GSK256066; Placebo
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииA Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00549679/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 40–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 104 чел. во всех странах исследования.
- Плановая дата окончания (12.2008) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 32
Критерии включения
- Male adults or female adults of non-childbearing potential who are between 40 and 75 years of age (inclusive).
- Subjects with a clinical diagnosis of COPD in accordance with the European Respiratory Society Consensus Statement and subjects categorised with moderate COPD as defined by the GOLD guidelines of 2006 \[GOLD, 2006\]
- Subjects with a cigarette smoking history of ≥ 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year or the equivalent). Both current and former smokers are eligible to be enrolled. A former smoker is defined as a subject who has not smoked for ≥6 months at Visit 1.
- Subjects with a post-bronchodilator FEV1 to FVC ratio (FEV1/FVC) < 0.7 at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg.
- Subjects with a post-bronchodilator FEV1 ≥ 50% and < 80% of predicted normal for height, age and sex at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg.
- Subjects with a normal echocardiogram at screening, as defined by the absence of clinically significant wall motion, chamber size or valvular abnormalities
- The subject must be capable of giving informed consent and can comply with the study requirements and timetable.
Критерии невключения
- Women who are pre-menopausal and of child-bearing potential.
- Subjects weighing less than 50 kilograms (kg).
- Subjects who are obese defined as having a body mass index (BMI) > 30.
- Subjects with a current diagnosis of asthma.
- Subjects who have required hospitalisation or treatment with oral corticosteroids and/or antibiotic therapy for acute worsening of COPD or lower respiratory tract infection in the 6 weeks prior to Screening.
- Subjects who have received treatment with oral, intravenous, topical or intra-articular corticosteroids within 6 weeks of Screening or thereafter
- Subjects with active tuberculosis, sarcoidosis or clinically overt bronchiectasis.
- Subjects with a history of any type of malignancy with the exception of successfully treated squamous cell cancer of the skin.
- Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).
- Subjects with chronic infections (lasting longer than 6 months) such as gingivitis, periodontitis, prostatitis, gastritis, and urinary tract infections.
- Subjects with any acute infection, sinus symptoms, or significant trauma (burns, fractures).
- Subjects with clinically significant renal disease, diabetes mellitus/metabolic syndrome, hypertension or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy.
- Subjects who have participated in any GSK study/studies involving administration of COA.
- The subject has a screening ECG parameters outside of ranges specified in protocol.
- Subjects with hypoxaemia
- Risk factors for human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection at Screening (Visit 1).
- Subjects who have undergone surgery including lung volume reduction surgery in the last six months or have conditions that prevent them from performing spirometry.
- Subjects with a history (or suspected history) of alcohol misuse or any other recreational substance abuse.
- Subjects who require treatment with any of the following from the start of the run-in period (Day -14) until the end of the treatment phase:
- Inhaled corticosteroids
- Inhaled cromolyn sodium or nedocromil
- Xanthines (theophylline preparations).
- Leukotriene modifiers
- Tiotropium
- Long-acting inhaled beta2-agonists (salmeterol, formoterol)
- Oral beta2-agonists
- Subjects who are unable to abstain from other courses of medication during the run in phase including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-histamines, anti-rhinitis or hay fever medication, other than short acting inhaled beta-agonists, ipratropium bromide and paracetamol (up to 4 g per day) for the treatment of minor ailments (eg headache) from 48h before the first dose until the follow-up visit. Subjects requiring medication between dosing and follow up may be excluded at the principal investigators discretion.
- Subjects with any known hypersensitivity to salbutamol or ipratropium bromide.
- Subjects who are participating or plan to participate in the active phase of a pulmonary rehabilitation programme during the study.
- Subjects who have received an investigational drug within 30 days or within five drug half-lives of the investigational drug (whichever is longer).
- Subjects with any clinically relevant abnormality detected by the assessments at Screening.
- Subjects who have experienced an exacerbation during the run-in period requiring treatment with oral corticosteroids and/or macrolide antibiotics and/or hospitalisation.
Источник: ClinicalTrials.gov, NCT00549679 · запись обновлена в реестре 28 июля 2017.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 23
- Number of participants with adverse events (AEs) and serious adverse events (SAEs) — Up to follow up (approximately 56 days)
- Change from Baseline (Day 0 [pre-bronchodilator]) in 12-lead electrocardiogram (ECG) findings — Baseline (Day 0 [pre-bronchodilator]) and up to Day 28 (Visit 6b)
- Change from Baseline (Day 0 [pre-bronchodilator]) in 12-lead electrocardiogram (ECG) findings-ventricular rate — Baseline (Day 0 [pre-bronchodilator]) and up to Day 28 (Visit 6b)
- Number of participants with abnormal (potential clinical importance [PCI]) systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) — Up to Day 27 (Visit 6a)
- Number of participants with abnormal (PCI) clinical chemistry — Up to Day 42 (follow up visit)
- Number of participants with abnormal (PCI) hematology — Up to Day 42 (follow up visit)
- Number of participants with abnormal urinalysis — Up to Day 56 (Visit follow up)
- Change from Baseline (Day 0) in lung function parameters: forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) — Baseline (Day 0) and up to Day 27 (Visit 6a)
- Number of participants with abnormal Holter interpretations — Up to Day 27 (Visit 6a)
- Number of participants who withdrawn for exacerbations of chronic obstructive pulmonary disease (COPD) — Up to Day 27 (Visit 6a)
Цель исследования
This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00549679 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.